Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

chemifarma s.p.a, italia - trimetoprim, - soluţie orală - Пуй, curcani, iepuri

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetul zaharat, tip 2 - medicamente utilizate în diabet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 și 5. 1 pentru datele disponibile pe diferite combinații).

Uniunea Europeană - română - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Uniunea Europeană - română - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Uniunea Europeană - română - EMA (European Medicines Agency)

theramex ireland limited - folitropină alfa - anovulația - hormoni sexuali și modulatori ai sistemului genital, - În adult womenanovulation (inclusiv sindromul ovarelor polichistice) la femei care nu au răspuns la tratamentul cu citrat de clomifen;stimularea multifollicular dezvoltare la femei în curs de superovulație pentru tehnologii de reproducere asistată (art), cum ar fi fertilizarea in vitro (fiv), transferul intrafalopian și transferul intrafalopian;ovaleap în asociere cu hormon luteinizant (lh) este recomandat pentru stimularea dezvoltării foliculare la femei cu sever de lh și fsh deficit. În studiile clinice la acești pacienți au fost definite printr-o concentrație plasmatică de lh endogen < 1. 2 ui/l. În adult menovaleap este indicat pentru stimularea spermatogenezei la bărbați care au congenitale sau dobândite hipogonadism hipogonadotropic concomitent cu gonadotropina corionica umana (hcg) terapie.

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, clorhidrat de metformină - diabetul zaharat, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 și 5. 1 pentru datele disponibile pe diferite combinații).

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leucemie, mielogenă, cronică, bcr-abl pozitivă - agenți antineoplazici - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sopharma ad - cetirizinum - comprimate filmate - 10 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sopharma ad - cetirizinum - sirop - 1 mg/ml